Biotech entity
Every one of those 1 sits in a single category, pharma. Arikayce is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. At 5, the average consequence score sits below the same-window beat average of 6.
Last mentioned: Feb 19, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, pharma. Arikayce is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. At 5, the average consequence score sits below the same-window beat average of 6. They are less corroborated than the beat average, carrying 2 original sources each against 2.4 for the same window. Brensocatib appears in 1 tracked Biotech story from February 19, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 27 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Brensocatib. Shared-story counts are live from our verified record — not editorial picks.
Insmed (INSM) enters its Q4 2025 earnings cycle at a critical inflection point as it transitions from a single-product company to a multi-asset commercial powerhouse. Investors are focused on Arikayce's revenue trajectory and the upcoming regulatory submission for brensocatib following its successful Phase 3 ASPEN trial.
Source: Seeking Alpha · Seeking Alpha
Brensocatib is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
